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Purpose. Propranolol has been successful in treating problematic infantile hemangiomas (IH) but concerns regarding its eﬀect on
normal growth and development have been raised. This study examines physical growth, developmental milestones, and human
growth hormone (hGH) levels in infants receiving propranolol for problematic IH. Method. Monthly heights and weights of
children undergoing propranolol therapy for IH were prospectively collected and tabulated. Data analysis and comparison to
World Health Organization (WHO) weight-for-age and weight-to-length z-scores was performed. Questionnaires regarding
milestones, eﬃcacy, and guardian satisfaction were performed, and a combination of both chart results and phone conducted
surveys was tabulated. Serum from a small representative cohort of age-matched children with IH treated and not treated with
propranolol was collected. Results. A total of 185 children receiving propranolol therapy between 2008 and 2013 for IH were
assigned to this study. The children were divided into two cohorts based on the presence of comorbidities or risk factors that
may aﬀect growth and development (n = 142 no comorbidities, n = 43 with comorbidities). Neither cohort demonstrated
deviation from normal weight in comparison to WHO normative data. There was a signiﬁcant deviation for BMI-for-age and
weight-for-age z-scores in our population, especially in patients on propranolol for more than 7 months. Based on data from
participants, via either completed questionnaires or chart results, most children met their developmental milestones at or before
target ages, regardless of the presence of comorbidities. Eighty percent of guardians noticed clinical improvement of the IH, with
91% either happy about or neutral to using the medication. hGH levels were higher in patients receiving propranolol therapy,
but not signiﬁcantly diﬀerent. Conclusion. Propranolol therapy is eﬀective and well tolerated in the treatment of infantile
hemangiomas. This study suggests that propranolol does not impair growth and has no impact on normal pediatric development.

1. Introduction
Infantile hemangiomas (IH) are benign tumors of blood vessels that, in general, start growing by the third month of life,
undergo a rapid growth phase for 6-8 months, and subsequently involute at a variable rate. They are the most common benign tumor of infancy, occurring in about 5% of
infants [1]. Most of them do not require treatment, but about

12% are problematic and prompt referral to a specialist and
require treatment [2]. IH characteristics that stimulate referral may include airway compromise, cosmetic deformity,
ulceration, bleeding, or functional loss, such as visual impairment or dysphagia. In the past, steroids, chemotherapy, laser
therapy, and surgery treatments were used for problematic
IH. These treatment options are becoming less necessary
after the serendipitous discovery by Leaute-Labreze et al.

2
[3] of early IH involution in a child treated with propranolol
for cardiomyopathy. Since that discovery, physicians have
embraced this therapy and are increasingly showing its success and safety.
Propranolol is a nonselective beta-blocker with a relatively low side eﬀect proﬁle, especially in healthy infants
[4]. The most common side eﬀects are sleep disturbance, dyspnea, nausea, somnolence, bradycardia, hypotension, hypoglycemia, and gastroesophageal reﬂux [5, 6]. However,
children treated with propranolol for IH are typically asymptomatic or experience mild hypotension or bradycardia [1].
Additionally, children with preexisting hypoglycemia have
been safely treated for infantile hemangiomas with propranolol [7]. Reported deaths and instances of heart failure associated with use of propranolol have been due to intravenous
propranolol or overdose [8]. Following FDA approval for the
treatment of IHs and its increasing use in institutions around
the world [3, 5, 9–17], the American Society of Pediatric Otolaryngology Vascular Anomalies Task Force approved its use
[1, 2]. Consensus conferences, international multicenter
studies (NCT01056341), and meta-analysis have all shown
the safety and eﬃcacy of propranolol [18], especially in comparison to steroids [19]. Erbay et al. [20] demonstrated safety
and eﬃcacy in preterm and low birth weight infants. Some
centers are successfully using a nonselective topical betablocker, such as timolol, with or without oral systemic propranolol to limit systemic toxicity [21, 22].
Although propranolol has been shown to have a clean
side eﬀect proﬁle, questions regarding the eﬀect of propranolol on normal growth and development have been raised
among physicians treating children with IH. Pediatricians
have questioned if potential long-term side eﬀects of prolonged therapy on growth and development could be justiﬁed
by the beneﬁts for nonlife-threatening hemangiomas.
This study prospectively and longitudinally examines 1st
year growth parameters (height and weight) and developmental milestones up to 48 months of age in infants treated
with oral propranolol on an outpatient basis. In addition, in
a small cohort of treated patients, human growth hormone
(hGH) levels were evaluated compared to age-matched normal controls. We hypothesize that propranolol does not
inﬂuence normal pediatric growth and development. It is
our hope that studies such as this will assuage these concerns
and validate its use for children with problematic IH.

2. Methods
Institutional Review Board approval 202187 and informed
consent were obtained. First, a retrospective review of prospectively collected data on heights and weights of children
on propranolol was performed. These values were recorded
from monthly dosing changes based on weight as recorded
by the patient’s PCP.
Patients were divided into two cohorts, those with
comorbidities that could aﬀect growth and development
and those without such comorbidities. The most common
reason a patient was determined to have a comorbidity was
a gestational age less than 36 weeks. Other factors were prolonged NICU stay (>2 weeks), congenital heart disease
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Table 1: Patient characteristics.
Gender
Male
Female

48
137

Median NICU length of stay (days)
Average NICU length of stay (days)

45
14
32
12
21

Birth history
Premature
Twin or triplet
NICU admission

Location of IH
Head and neck
Trunk
Extremity
Multifocal
Unknown
Comorbidities that may aﬀect growth or development
Yes
No
Cardiac abnormalities
Laryngomalacia
Non-hemangioma surgery
Gestational history (mother)
Preeclampsia
Gestational diabetes
Placental abnormalities
First trimester bleeding
Trauma
Hypertension
Tobacco or alcohol
Amniocentesis
Chorionic villus sampling
Other medications
None
Antacid (PPI or H2 blocker)
Systemic steroid
Other

130
8
15
31
1
43
142
16
5
23
23
11
12
15
23
23
8
3
0
53
61
5
59

requiring surgery (excluding patent ductus arteriosus unless
also coarctation of the aorta), congenital airway anomalies,
adrenal insuﬃciency, hypothyroidism, and failure to thrive.
Diseases such as asthma, eczema, autism, ADHD, and isolated low birth weight were not considered signiﬁcant to
growth and development. Patients presented to our outpatient vascular anomalies clinic for follow-up after initiation
of propranolol. The mean follow-up time was 7.2 months.
The weight-for-age, BMI-for-age, and weight-to-length z
-scores were calculated and compared to normative World
Health Organization (WHO) values for pediatric growth. A
mixed eﬀects model was created with an unstructured covariance matrix to analyze weight, weight-for-age, weight-forlength, and BMI-for-age z-scores and percentiles. Random
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intercepts and random slopes were evaluated by testing
nested models using likelihood ratio tests.
In order to determine age of milestone achievement, side
eﬀects, eﬃcacy, other treatments, and satisfaction with the
therapy up to 48 months posttreatment, guardians were surveyed retrospectively, and additional chart results were tabulated. In a representative cohort, serum from age-matched
children with IH treated and untreated with propranolol
was collected for the determination of human growth hormone (hGH) levels during the course of their treatment.

3. Results
One hundred and eighty-ﬁve patients were included in the
study, 48 males and 137 females (Table 1). Multiple gestation
(twins and triplets) was found in 7.6% of the population.
Eighty-eight patients had heights and weights while 97
patients had weight alone. Questionnaires regarding milestones, eﬃcacy, and guardian satisfaction were performed
on 174 patients, and a combination of both chart results
and phone conducted surveys were tabulated. Thirty-eight
patients had hGH measured; 11 of whom were on propranolol with the remaining untreated and healthy age matched.
Serum measurements were drawn only on patients in the
cohort undergoing anesthesia for related or unrelated procedures. Blood draws were considered too invasive in the clinic
setting for this study.
There were 142 patients without and 43 patients with
comorbidities that aﬀect growth and development
(Table 1). Birth weight in the patients was signiﬁcantly lower
in the cohort with comorbidities (p < 0:0001) suggesting
patients were appropriately chosen for the cohort without

hGH (ng/mL)

Figure 1: Treated and nontreated patients’ z-scores compared to WHO standards.

Nontreated

Propranolol
treated

Figure 2: Mean hGH level in propranolol-treated (6.38 ng/mL)
versus non-treated hemangioma patients (4.59 ng/mL).
SD =3.15 ng/mL, p = 0:16.

comorbidities. Laryngomalacia was reported in 5 patients,
and cardiac anomalies were reported in 16 patients.
Twenty-three patients had general anesthesia for surgery
for something other than IH.
One patient whose guardian completed the questionnaire
was excluded in the developmental portion due to global
developmental delay, and another questionnaire was stopped
short due to a cerebrovascular injury. If a parent could not
recall the age at which milestones were achieved, that portion
of the questionnaire was excluded. Families may not have
responded to all the questions in the survey. Results reﬂect
the total number of respondents for each question.
Of note, thirty-two (17.3%) patients required a postnatal
NICU admission unrelated to IH therapy with a length of
staying ranging from 2 to 98 days and a median of 12 days.
Fifty-eight were on medications other than propranolol.
The most common unrelated pediatric condition was
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Table 2: Guardian reported side eﬀects.

Side eﬀect
None
Reﬂux
Spit up more
Respiratory problems
Lethargy
Sleep disturbance
Mood alteration
Sweating
“Sickly”
Hyperactivity
Polyuria
Allergy
Gastritis

Patients (% of total)
115 (62)
27 (15)
19 (10)
13 (7)
9 (5)
8 (4)
6 (3)
2 (1)
2 (1)
2 (1)
1(<1)
1(<1)
1(<1)

gastroesophageal reﬂux, and accordingly, the most common
other medication was a reﬂux medication such as an H2
blocker or a proton pump inhibitor (62 patients).
3.1. Anthropomorphic Measurements. The age-matched control heights and weights were compared in the propranolol
treated and nontreated groups. The anthropomorphic data
show patients in both cohorts were within or above the
WHO normative values (Figure 1 and Supplementary Table
1). Some patients in our study population have higher
weight-for-length and higher BMI-for-age than the WHO
normative population. This observation seems to correlate
with time on propranolol therapy (Supplementary Table 2).
hGH levels were 6.38 ng/mL for propranolol-treated patients
compared to 4.59 ng/ml in nontreated patients (Figure 2).
This represents a standard deviation of 3.15 ng/ml and a p
value of 0.16.

Table 3: Eﬃcacy, side eﬀects, and adjuvant therapy of propranolol
based on guardian survey. Guardians may not have responded to
each survey question thus creating variability in the number of
respondents per question.
Eﬃcacy
Did not notice improvement
Time to notice an improvement

3.3. Patient Satisfaction and Eﬃcacy. Most guardian respondents reported that they were happy with the propranolol
therapy 88/114 (77%); 16/114 (14%) were neutral, and
10/114 (9%) were unhappy. 152 families reported clinical
(80%) improvement in color, size, or both. 107/154 (69.5%)
noticed a color change and 152/174 (87.3%) reported a
decrease in size of the IH, most within one month of starting
therapy (60/89, 67.4%). Twelve percent of patients had
rebound after propranolol was stopped, and 73.9% of
patients had a second type of treatment (laser, surgery, or
injection) (Table 3). Ninety-three (53.4%) patients had laser
therapy in addition to the propranolol.

10
34
32
16
13
95

Yes
No

121 (76)
39 (24)

Yes
No

158 (88)
22 (22)

Happy
Neutral
Unhappy

94 (78)
16 (13)
10 (8)

Yes
No

62 (34)
118 (66)

Yes
No

17 (13)
110 (87)

Laser
Surgery
Steroid
Scar revision
Vincristine

97 (54)
73 (41)
35 (19)
1 (<1)
3 (1)

Color change
160
Decreased size
180
Overall satisfaction
120

Side eﬀects
180

Recurrence/rebound
127
Adjuvant treatments∗
180

3.2. Side Eﬀects. Twelve side eﬀects from propranolol were
reported in 70/185 (37.8%) patients but rarely led to drug
cessation (Table 2). The most common side eﬀect was reﬂux,
found in 27 (15%) patients. Of note, 44 patients had symptomatic reﬂux before starting propranolol therapy, and 12
diﬀerent questionnaire respondents reported it as a side
eﬀect. Other side eﬀects included respiratory disturbances
(n = 13), lethargy (n = 9), and sleep disturbance (n = 8).

Less than one week
Less than one month
1-2 months
More than 2 months

∗

Note: some patients had multiple treatments.

3.4. Milestones. Based on the questionnaire respondents and
chart results, patients met gross and ﬁne motor milestones
at or before the expected target age (Figure 3). This is true
in both cohorts with or without comorbidities. Furthermore,
by 4 years of age (Figure 4), less than 20% had not reached
their expected milestone. Milestone achievement was not
impacted by the presence of comorbidities that aﬀect growth
and development (Table 3).

4. Discussion
Propranolol has been in use for the treatment of infantile
hemangiomas since 2008 and is well tolerated as evidenced
in the present study. Although 12 diﬀerent side eﬀects were
reported, some may have been observations and not directly
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Total
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0
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36

48
Milestone (month)
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Patients (points) below target-age-line achieved milestone early
(a) Gross motor skills

(b) Fine motor skills

Age skill achieved (month)

Linear representation of fine and gross motor skill achievement
Gross motor skills
50
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10
0
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18
24
36
Milestone (month)

48

Age skill achieved (month)

Fine motor skills
50
40
30
20
10
0
4 6 9 12

18

24

36

48

Milestone (month)
Without comorbidities
With comorbidities
(c) Linear representation of ﬁne and gross motor skill achievement

Figure 3: Patients treated with propranolol compared to expected developmental milestone. Each dot represents a patient at a moment in
time. Patients below the target line reached the milestone before the target age.

related to propranolol use. Fifteen percent of our population
reported reﬂux as a side eﬀect. Although “spitting up” and
“reﬂux” are diﬃcult to distinguish, 10% of guardians thought
that their children spit up more on propranolol.
In addition to being well tolerated, propranolol is known
to be a successful treatment for infantile hemangiomas. In
our study, most respondents were happy with the therapeutic
eﬀect. However, almost 74% of our population received secondary treatment, with the majority (53.4%) of those receiving laser therapy. Laser therapy was performed to control

symptoms such as bleeding or as a cosmetic adjunct for
remaining tissue rather than for a propranolol treatment
failure. A ﬂash pump dye laser at 595 nm was used for this
purpose. In most cases that required surgical excision, propranolol was used preoperatively, and surgery was then performed to remove remaining anetoderma or scar revision.
All indices of eﬃcacy, satisfaction, and side eﬀects were not
diﬀerent between the cohorts with and without comorbidities.
Though there is not a single human study showing developmental delay or growth retardation due to propranolol,
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Figure 4: Patients treated with propranolol compared to expected developmental milestone. Number of patients per age that achieved 4month milestone and percentage of patients per age that achieved 4-month milestone.

concern might have been derived from previous studies
showing intrauterine growth restriction (IUGR) and
decreased perinatal growth in rats who were born to dams
on beta-blockers [23, 24]. Another animal study showed propranolol caused body weight deﬁcits up to 33% [25]. Of note,
this was at a dose of 75 mg/kg lavaged into suckling rats.
Based on consensus data propranolol dose used to treat IH
is recommended to be 2-3 mg/kg/day [2]. Thus the lower
dose of propranolol given to humans should not pose the
same threat as the high dose used in rat studies. In fact, recent
work by Moyakine et al. demonstrated no impact of low dose
propranolol on human growth and development up to 4
years of age in infants treated for IH. The present ﬁndings
refute prior animal investigations and corroborates prior
human investigations.
Contrary to the concerns about pediatric growth, Ghigo
et al. demonstrated beta-adrenergic antagonism increases
growth hormone releasing hormone-induced GH secretion
[26]. There is no known correlation between IH and growth
hormone except one case of GH deﬁciency in a patient with
facial hemangioma in the context of PHACE syndrome
[27]. Accordingly, measurement of growth hormone in this
study was chosen as an added objective measurement of
pediatric growth in addition to heights and weights with evidence of higher hGH levels in patients treated with propranolol. Similarly, Altin et al. demonstrated that the physical
growth rate of patients with a mean age of 2.64 was not
aﬀected by propranolol [28].

Because propranolol has been shown to aﬀect the consolidation of memory [29], a concern was expressed that this
may aﬀect cognitive development in children. However, a
study including 36 children with infantile hemangiomas on
oral propranolol showed no eﬀect on neurodevelopmental
outcomes or CNS development [30], as well as another study
in propranolol-treated children aged ﬁve to seven-and-a-half
years old that showed no signiﬁcant evidence of intelligence
or memory development disturbance [31].
Our data suggest propranolol is a well-tolerated, eﬀective
treatment that does not impair normal growth and development. Although great lengths were taken to separate patients
into two cohorts (with and without comorbidities) to better
assess whether delay in growth or development was due to
those factors, no appreciable diﬀerence was noted between
the groups. Remarkably, without dividing the participants
into two cohorts, there was not a statistically signiﬁcant difference in milestones or growth at four years of age. This suggests these patients “catch up” developmentally.
Explanations and validation of the ability to “catch up” in
the face of seemingly growth-aﬀecting comorbidities is
beyond the scope of this paper.
Our data show hGH levels are not aﬀected by propranolol therapy, but there are many factors other than hGH
involved in pediatric growth that were not measured. Most
children undergoing systemic propranolol treatment for IH
did not have growth alterations. We were surprised to ﬁnd
some patients treated with propranolol had a higher
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weight-for-length BMI compared to WHO normative data.
Although lengths and weights were within the 95th percentile, the average BMI was higher. The initial concern of
growth impairment is diminished; however, this may introduce a paradoxical concern of abnormal weight gain.
Care must be taken not to interpret this observation as a
direct result of propranolol therapy. There is a population
bias as this is a single-center study, and there is no control
group of patients with hemangiomas not receiving therapy
with whom to compare. There may also be a selection bias
in the population of patients that presented to the center.
These issues warrant further investigation. There are reports
of patients taking propranolol for migraine that have experienced weight gain [32, 33]. However, this issue has not been
studied in the pediatric population except for one study
showing weight gain in a patient on prolonged propranolol
therapy for 6-12 months [34].
As propranolol is a relatively new therapy for infantile
hemangiomas, long-term studies are still ongoing to
completely evaluate the eﬀects of propranolol in the pediatric
population. This study does not evaluate other reported side
eﬀects of propranolol such as hypoglycemia, insomnia, and
bradycardia; therefore, it is not a comprehensive study of
propranolol safety. Furthermore, the primary aim of this
study was not to examine the eﬃcacy of propranolol for hemangiomas, which have been previously shown in other studies [3, 9, 35] but instead to report the ﬁndings of the
relationship between propranolol use, growth, and
development.
Because therapy is eﬀective and complete for most
patients by one year of age, most patients do not follow in
our clinic after the involution of the lesion for the 12 to 48month period of milestone assessment. Thus, the questionnaire regarding milestone achievement after age one was
completed by phone retrospectively. This methodology
introduced recall bias.

5. Conclusion
We conclude that propranolol does not cause growth or
developmental delay. This supports existing literature showing its safety in pediatric patients for the treatment of infantile hemangioma. Further study is warranted to evaluate the
role of propranolol in the increase in weight-for-age and
weight-for-length.

Data Availability
Data is available upon request. Please contact gtrichter@uams.edu if more information is required.

Conflicts of Interest
The authors declare that they have no conﬂicts of interest.

Acknowledgments
The authors would like to thank the following individuals for
their contributions to this body of work.

7

Supplementary Materials
Supplementary tables were included to provide the reader
with further information regarding the number of children
above and below WHO z-scores, as well as the relationship
between anthropometric measurements and the length of
propranolol therapy. (Supplementary Materials)

References
[1] D. Krowchuk, I. Frieden, A. Mancini et al., “Clinical practice
guideline for the management of Infantile Hemangiomas,”
Pediatrics, vol. 143, no. 1, article e20183475, 2019.
[2] B. A. Drolet, P. C. Frommelt, S. L. Chamlin et al., “Initiation
and use of propranolol for infantile hemangioma: report of a
consensus conference,” Pediatrics, vol. 131, no. 1, pp. 128–
140, 2013.
[3] C. Léauté-Labrèze, E. D. de la Roque, T. Hubiche, F. Boralevi,
J. B. Thambo, and A. Taïeb, “Propranolol for severe hemangiomas of infancy,” The New England Journal of Medicine,
vol. 358, no. 24, pp. 2649–2651, 2008.
[4] R. Hagen, E. Ghareeb, O. Jalali, and Z. Zinn, “Infantile hemangiomas: what have we learned from propranolol?,” Current
Opinion in Pediatrics., vol. 30, no. 4, pp. 499–504, 2018.
[5] I. J. Frieden and B. A. Drolet, “Propranolol for infantile hemangiomas: promise, peril, pathogenesis,” Pediatric Dermatology, vol. 26, no. 5, pp. 642–644, 2009.
[6] L. P. Lawley, E. Siegfried, and J. L. Todd, “Propranolol treatment for hemangioma of infancy: risks and recommendations,” Pediatric Dermatology, vol. 26, no. 5, pp. 610–614,
2009.
[7] T.-L. Yang, P. McMahon, D. De León, and J. Treat, “Use of
propranolol for treating hemangiomas in infants with previously diagnosed hypoglycemic conditions,” Pediatric Dermatology, vol. 33, no. 6, pp. 381–384, 2016.
[8] J. N. Love, T. L. Litovitz, J. M. Howell, and C. Clancy, “Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to
1995,” Journal of Toxicology. Clinical Toxicology, vol. 35,
pp. 353–359, 2009.
[9] L. M. Buckmiller, P. D. Munson, U. Dyamenahalli, Y. Dai, and
G. T. Richter, “Propranolol for infantile hemangiomas: early
experience at a tertiary vascular anomalies center,” Laryngoscope, vol. 120, no. 4, pp. 676–681, 2010.
[10] A. Georgountzou, E. Karavitakis, A. Klimentopoulou,
A. Xaidara, and T. Kakourou, “Propranolol treatment for
severe infantile hemangiomas: a single-centre 3-year experience,” Acta Paediatrica, vol. 101, no. 10, pp. e469–e474, 2012.
[11] S. R. Parikh, D. H. Darrow, J. F. Grimmer, S. C. Manning, G. T.
Richter, and J. A. Perkins, “Propranolol use for infantile hemangiomas,” JAMA Otolaryngology. Head & Neck Surgery,
vol. 139, no. 2, pp. 153–156, 2013.
[12] G. T. Richter and A. B. Friedman, “Hemangiomas and vascular
malformations: current theory and management,” International Journal Of Pediatrics, vol. 2012, Article ID 645678, 10
pages, 2012.
[13] R. Sidbury, “Update on vascular tumors of infancy,” Current
Opinion in Pediatrics, vol. 22, no. 4, pp. 432–437, 2010.
[14] A. P. Zimmermann, S. Wiegand, J. A. Werner, and B. Eivazi,
“Propranolol therapy for infantile haemangiomas: review of

8

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]
[26]

[27]

[28]

[29]

International Journal of Pediatrics
the literature,” International Journal of Pediatric Otorhinolaryngology, vol. 74, no. 4, pp. 338–342, 2010.
A. L. Marqueling, V. Oza, I. J. Frieden, and K. B. Puttgen, “Propranolol and infantile hemangiomas four years later: a systematic review,” Pediatric Dermatology, vol. 30, no. 2, pp. 182–191,
2013.
K. W. Rosbe, K. Y. Suh, A. K. Meyer, S. M. Maguiness, and I. J.
Frieden, “Propranolol in the management of airway infantile
hemangiomas,” Archives of Otolaryngology – Head & Neck
Surgery, vol. 136, no. 7, pp. 658–665, 2010.
A. Zvulunov, C. McCuaig, I. J. Frieden et al., “Oral propranolol
therapy for infantile hemangiomas beyond the proliferation
phase: a multicenter retrospective study,” Pediatric Dermatology, vol. 28, no. 2, pp. 94–98, 2011.
C. Leaute-Labreze, P. Hoeger, J. Mazereeuw-Hautier et al., “A
randomized, controlled trial of oral propranolol in infantile
hemangioma,” New England Journal of Medicine, vol. 372,
no. 8, pp. 735–746, 2015.
A. Izadpanah, A. Izadpanah, J. Kanevsky, E. Belzile, and
K. Schwarz, “Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and
meta-analysis,” Plastic and Reconstructive Surgery, vol. 131,
no. 3, pp. 601–613, 2013.
A. Erbay, F. Sarialioglu, B. Malbora et al., “Propranolol for
infantile hemangiomas: a preliminary report on eﬃcacy and
safety in very low birth weight infants,” Turkish Journal of
Pediatrics, vol. 52, no. 5, p. 450, 2010.
M. G. Kumar, C. Coughlin, and S. J. Bayliss, “Outpatient use of
oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines,” Pediatric Dermatology, vol. 32,
no. 2, pp. 171–179, 2015.
J. Ge, J. Zheng, L. Zhang, W. Yuan, and H. Zhao, “Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study,” Scientiﬁc Reports,
vol. 6, no. 1, p. 19765, 2016.
N. Schoenfeld, O. Epstein, L. Nemesh, M. Rosen, and
A. Atsmon, “Eﬀects of propranolol during pregnancy and
development of rats. I. Adverse eﬀects during pregnancy,”
Pediatric Research, vol. 12, no. 7, pp. 747–750, 1978.
N. Schoenfeld, O. Epstein, M. Rosen, and A. Atsmon, “Eﬀects
of propranolol during pregnancy and development of rats. II.
Adverse eﬀects on development,” European Journal of Pediatrics, vol. 143, no. 3, pp. 194-195, 1985.
G. Redmond, “Propanolol inhibits brain and somatic growth
in the rat,” Nature, vol. 15, p. 645, 1981.
A. V. Moyakine, J. M. Kerstjens, S. Spillekom-van Koulil, and
C. J. M. van der Vleuten, “Propranolol treatment of infantile
hemangioma (IH) is not associated with developmental risk
or growth impairment at age 4 years,” Journal of the American
Academy of Dermatology, vol. 75, no. 1, pp. 59–63.e1, 2016.
E. Ghigo, J. Bellone, E. Arvat et al., “Eﬀects of alpha- and betaadrenergic agonists and antagonists on growth hormone secretion in man,” Journal of Neuroendocrinology, vol. 2, no. 4,
pp. 473–476, 1990.
H. Altin, H. Alp, F. Şap, Z. Karataş, T. Baysal, and S. Karaaslan,
“PHACE syndrome with growth hormone deﬁciency and
absence of bilateral internal carotid arteries: a case report,”
Pediatric Dermatology, vol. 29, no. 3, pp. 316–319, 2012.
L. Hu, B. Zhou, H. Huang et al., “Eﬀects of systemic propranolol treatment on physical growth of patients with infantile

[30]

[31]

[32]

[33]

[34]

[35]

hemangiomas,” Journal of Dermatology, vol. 43, no. 10,
pp. 1160–1166, 2016.
M. H. Lonergan, L. A. Olivera-Figueroa, R. K. Pitman, and
A. Brunet, “Propranolol’s eﬀects on the consolidation and
reconsolidation of long-term emotional memory in healthy
participants: a meta-analysis,” Journal of Psychiatry & Neuroscience, vol. 38, no. 4, pp. 222–231, 2013.
C. Wang, W. Wang, B. Xiang, S. Chen, F. Xiong, and Y. Ji,
“Eﬀects of Propranolol on Neurodevelopmental Outcomes in
Patients with Infantile Hemangioma: A Case-Control Study,”
BioMed Research International, vol. 2018, Article ID
5821369, 6 pages, 2018.
L. Tang, J. W. Hing, J. Tang et al., “Predicting complications
with pretreatment testing in infantile haemangioma treated
with oral propranolol,” British Journal of Ophthalmology,
vol. 100, no. 7, pp. 902–906, 2016.
F. R. Taylor, “Weight change associated with the use of
migraine-preventive medications,” Clinical Therapeutics,
vol. 30, no. 6, pp. 1069–1080, 2008.
I. Martinez-Mir, J. Navarro-Badenes, V. Palop, F. J. MoralesOlivas, and E. Rubio, “Weight gain induced by long-term propranolol treatment,” The Annals of Pharmacotherapy, vol. 27,
no. 4, p. 512, 1993.
M. Oksiuta, E. Matuszczak, W. Dębek, E. Dzienis-Koronkiewicz, A. Hermanowicz, and M. Tylicka, “Treatment of problematic infantile hemangiomas with propranolol: a series of
40 cases and review of the literature,” Postȩpy Higieny i Medycyny Doświadczalnej (Online), vol. 68, pp. 1138–1144, 2014.

